

## UNITED STATES PATENT AND TRADEMARK OFFICE

Plane of h					www.us
U.S. APPLICATION NO.		FIRST NAMED APPLICAN	Т		ATTY, DOCKET NO.
09/831335 MALLET  AVENTIS PHARMACEUTICALS, INC. PATENTS DEPARTMENT ROUTE 202-206, P.O. BOX 6800 BRIDGEWATER, NJ 08807 0800		MALLET	J	ST 98036-US-	
			INTERNATIONAL APPLICATION NO.		
		PCT/FR99/02752			
			I.A. FILIN	IG DATE	PRIORITY DATE
DINDOLIVATEIN, NO 00007 00007	09 NO		V 99	09 NOV 98	
			O. TE	9	) 5   H   2001

## NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

The application fails to comply with the requirements of 37 CFR 1.821-1.825.
This application does not contain, a "Sequence Listing" as a separate part of the
disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
A copy of the "Sequence Listing" in computer readable format has not been submitted as
required by 37 CFR 1.821(e).
A copy of the "Sequence Listing" in computer readable form has been submitted. The
content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
The computer readable form that has been filed with this application has been found to be
damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).  The paper copy or compact disc of the "Sequence Listing" is not the same as the
computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
Other:
APPLICANT MUST PROVIDE:
An initial or substitute computer readable form (CRF) of the "Sequence Listing."
An initial or substitute computer readable form (CRF) of the "Sequence Listing."  An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.  A statement that the contents of the paper or compact disc and the computer readable form
An initial or substitute computer readable form (CRF) of the "Sequence Listing."  An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
An initial or substitute computer readable form (CRF) of the "Sequence Listing."  An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.  A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR
An initial or substitute computer readable form (CRF) of the "Sequence Listing."  An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.  A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).  FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CALL:  (703) 308-4216, for Rules interpretation,
An initial or substitute computer readable form (CRF) of the "Sequence Listing."  An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.  A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).  FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CALL:

Christine S. Washington

Telephone: 703-305-3752